Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 96

Sort by

Sort Order Select

Journal Articles

Results of PAC203: A Randomized Phase 2 Dose-Finding Study and Determination of the Recommended Dose of Pacritinib

Aaron T. Gerds, MD MS, Michael R. Savona, MD, Bart L. Scott, MD, Moshe Talpaz, MD, Miklos Egyed, Claire N Harrison, Professor, Abdulraheem Yacoub, MD, Alessandro M. Vannucchi, MD, Adam J. Mead, MD PhD, Jennifer O'Sullivan, Sarah A Buckley, MD, Diane R. Mould, PhD, Shanthakumar Tyavanagimatt, PhD, Jennifer A. Smith, PhD, John Mascarenhas, MD

Blood (2019) 134 (Supplement_1): 667.

https://doi.org/10.1182/blood-2019-129293

Published: 2019

Journal Articles

Post-Transplant Cyclophosphamide in Allogeneic Bone Marrow Transplantation for the Treatment of Benign Hematologic Diseases

Mark Leick, MD, Bradley Hunter, MD MPH, Zachariah Defilipp, MD, Bimalangshu Dey, MD, Areej El-Jawahri, MD, Matthew J. Frigault, MD, Steven L McAfee, MD, Thomas Spitzer, MD, Paul V. O'Donnell, MD PhD, Yi-Bin Chen

Blood (2019) 134 (Supplement_1): 1978.

https://doi.org/10.1182/blood-2019-128295

Published: 2019

Journal Articles

In-Hospital Mortality and Morbidity Among Patients Presenting with Intracranial Hemorrhage: A Single Center's Experience with Vitamin K Antagonists and the Direct Oral Anticoagulants

Christopher Cipkar, MD BSc, Sujitha Srinathan, Philip Chiang, BMSc, Lana A Castellucci, MD FRCPC, MSc

Blood (2019) 134 (Supplement_1): 3668.

https://doi.org/10.1182/blood-2019-131769

Published: 2019

Journal Articles

Efficacy and Safety of CPX-351 Versus 7+3 in a Phase 3 Exploratory Analysis in Patients with High-Risk/Secondary Acute Myeloid Leukemia (AML) with Prior Hypomethylating Agent Exposure Who Achieved Remission

Tara L. Lin, MD, Daniel H. Ryan, MD, Ellen K. Ritchie, MD, Stephen A. Strickland, MD, Donna E. Hogge, MD PhD, Scott R. Solomon, MD, Jonathan E. Kolitz, MD, Gary J. Schiller, MD, Matthew J. Wieduwilt, MD PhD, Robert J. Ryan, MS, Stefan Faderl, MD, Jorge E. Cortes, MD

Blood (2019) 134 (Supplement_1): 1316.

https://doi.org/10.1182/blood-2019-124552

Published: 2019

Journal Articles

An Analysis from the WM UK Rory Morrison Registry - How Does Waldenström's Macroglobulinemia Affect Younger Patients?

Oliver Tomkins, BMBS, MRCP, Joshua Bomsztyk, Helen McCarthy, MBBS, PhD, Jaimal Kothari, Dima El-Sharkawi, Charalampia Kyriakou, Guy Pratt, Ali Rismani, MBBS, Shirley D'Sa

Blood (2019) 134 (Supplement_1): 1543.

https://doi.org/10.1182/blood-2019-123693

Published: 2019

Journal Articles

Risk of Hemorrhage in Patients with Polycythemia Vera Exposed to Aspirin in Combination with Anticoagulants: Results of a Prospective, Multicenter, Observational Cohort Study (REVEAL)

Jeffrey I. Zwicker, MD, David S. Lessen, MD, Philomena Colucci, DO, MS, Dilan Paranagama, PhD, Michael R. Grunwald, MD

Blood (2019) 134 (Supplement_1): 168.

https://doi.org/10.1182/blood-2019-123835

Published: 2019

Journal Articles

Blinatumomab in Combination with Pembrolizumab Is Safe for Adults with Relapsed or Refractory B-Lineage Acute Lymphoblastic Leukemia: University of California Hematologic Malignancies Consortium Study 1504

Marc Schwartz, MD, Lloyd E. Damon, MD, Deepa Jeyakumar, MD, Caitlin L. Costello, MD, Dimitrios Tzachanis, MD PhD, Gary J. Schiller, MD, Jesika Reiner, MPH, Matthew J. Wieduwilt, MD PhD

Blood (2019) 134 (Supplement_1): 3880.

https://doi.org/10.1182/blood-2019-131061

Published: 2019

Journal Articles

Venetoclax and Cytarabine in AML Transformed from Myelofibrosis

John McKay, DO, Matthew Gayhart, MD, Taha Al-Juhaishi, MD, Victor Yazbeck, MD, Edward B. Perkins, MD PhD

Blood (2019) 134 (Supplement_1): 5140.

https://doi.org/10.1182/blood-2019-129429

Published: 2019

Journal Articles

A Prospective, Open-Label, Multicenter, Phase 2 Trial to Evaluate the Safety and Efficacy of the Combination of Tirabrutinib (ONO/GS-4059) and Entospletinib with and without Obinutuzumab in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL)

Nadine Kutsch, MD, Christian Pallasch, Eugen Tausch, Volkmar Boehme, Matthias Ritgen, Ruediger Liersch, Alexander Wacker, Georg Jacobs, Ralf Ulrich Trappe, Peter Dreger, Stephan Stilgenbauer, Danjie Zhang, Juliane M. Jürgensmeier, Pankaj Bhargava, Michael Hallek, Barbara F. Eichhorst, MD

Blood (2019) 134 (Supplement_1): 4297.

https://doi.org/10.1182/blood-2019-130912

Published: 2019

Journal Articles

A Phase 1 First-in-Human Study of AMG 330, an Anti-CD33 Bispecific T-Cell Engager (BiTE ® ) Antibody Construct, in Relapsed/Refractory Acute Myeloid Leukemia (R/R AML)

Farhad Ravandi, MD, Anthony S. Stein, MD, Hagop M. Kantarjian, MD, Roland B. Walter, MD PhD MS, Peter Paschka, MD, Mojca Jongen-Lavrencic, MD PhD, Gert J. Ossenkoppele, MD PhD, Zhao Yang, Bhakti Mehta, Marion Subklewe, MD

Blood (2018) 132 (Supplement 1): 25.

https://doi.org/10.1182/blood-2018-99-109762

Published: 2018

Journal Articles

Characteristics of Patients (pts) Who Relapse and Die of Multiple Myeloma (MM) within One Year Post Frontline Autologous Stem Cell Transplant (ASCT) in the Novel Agent Era: An Ultra-High Risk Population

Hatem Alahwal, MPH, MBBS, Heather J. Sutherland, MD PhD, Shruthi Ganeshappa Kodad, MD, Stephen H. Nantel, MD, Yasser Abou Mourad, MD, Michael J. Barnett, BMBS, Donna L. Forrest, MD, Alina S. Gerrie, MD MPH, Donna E. Hogge, MD PhD, Sujaatha Narayanan, MBBS, MRCP, MRCPath, Thomas J. Nevill, MD, Maryse Power, MD, David Sanford, MD, Cynthia L. Toze, MD FRCPC, MSc, Jennifer White, MD, Raewyn Broady, MBChB, Kevin Song, MD

Blood (2018) 132 (Supplement 1): 3440.

https://doi.org/10.1182/blood-2018-99-111533

Published: 2018

Journal Articles

Low-Dose Lenalidomide Maintenance after Induction Therapy in Older Patients with Primary CNS Lymphoma

Khoan Vu, MD, James Rubenstein, MD PhD, Gabriel N. Mannis, MD, Jimmy Hwang, PhD, Huimin Geng, PhD

Blood (2018) 132 (Supplement 1): 4230.

https://doi.org/10.1182/blood-2018-99-112767

Published: 2018

Journal Articles

Safety and Efficacy of Acalabrutinib Plus Bendamustine and Rituximab (BR) in Patients with Treatment-Naive (TN) or Relapsed/Refractory (R/R) Mantle Cell Lymphoma (MCL)

Tycel J. Phillips, MD, Stephen D. Smith, MD, Wojciech Jurczak, Tadeusz Robak, MD PhD, Don Stevens, MD, Charles M. Farber, MD PhD, John M. Pagel, MD PhD, Kami J. Maddocks, MD, Ian W. Flinn, MD PhD, Wieslaw W. Jedrzejczak, MD PhD, Andre Goy, MD, Pier Luigi Zinzani, MD, Jan Zaucha, MD PhD, Morton Coleman, MD, Tianling Chen, MD, Sun Ku Lee, PhD, Wei Liang, PhD, Anna Seto, PharmD, Michael Wang, MD

Blood (2018) 132 (Supplement 1): 4144.

https://doi.org/10.1182/blood-2018-99-110617

Published: 2018

Journal Articles

Low Molecular Weight Heparin (LMWH) for Venous Thromboembolism (VTE) Prophylaxis in Patients with Primary Central Nervous System Lymphoma (PCNSL)

Deborah Rund, MD, Stav Gazal, BSc, Yosef Kalish, MD, Chen Makranz, MD, Neta Goldschmidt, MD

Blood (2018) 132 (Supplement 1): 2993.

https://doi.org/10.1182/blood-2018-99-119154

Published: 2018

Journal Articles

Comparison of Efficacy and Toxicity of CD19-Specific Chimeric Antigen Receptor T-Cells Alone or in Combination with Ibrutinib for Relapsed and/or Refractory CLL

Blood (2018) 132 (Supplement 1): 299.

https://doi.org/10.1182/blood-2018-99-111061

Published: 2018

Journal Articles

Up to 7 Years of Follow-up of Single-Agent Ibrutinib in the Phase 1b/2 PCYC-1102 Trial of First Line and Relapsed/Refractory Patients with Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

John C. Byrd, MD, Richard R. Furman, MD, Steven Coutre, MD, Ian W. Flinn, MD PhD, Jan A. Burger, MD PhD, Kristie A. Blum, MD, Jeff Sharman, MD, William G. Wierda, MD PhD, Weiqiang Zhao, MD PhD, Nyla A. Heerema, PhD, Ying Luan, PhD, Emily A. Liu, PhD, James P. Dean, MD PhD, Susan M. O'Brien, MD

Blood (2018) 132 (Supplement 1): 3133.

https://doi.org/10.1182/blood-2018-99-110847

Published: 2018

Journal Articles

Intracranial Hemorrhage in Children with Inherited Bleeding Disorders: A Single Center Study in China

Qareen Haque, Chunfu Li, MD, Yilifan Abuduaini, Xiaoqin Feng, PhD

Blood (2017) 130 (Supplement 1): 4896.

https://doi.org/10.1182/blood.V130.Suppl_1.4896.4896

Published: 2017

Journal Articles

Outcomes of Autologous Stem Cell Transplantation in Very Elderly Patients with Multiple Myeloma

Phyllis McKiernan, APN, MSN, David Siegel, MD PhD, David H. Vesole, MD PhD, Scott D. Rowley, MD, Tracy Andrews, PhD, Andrea Ortega, RN, Alan P Skarbnik, MD, Noa Biran, MD, Joshua R Richter, MD, Andrew L. Pecora, MD, Andre Goy, MD, Rima M Panchal, MD, Nino Aleksidze, MD, Michele L. Donato, MD

Blood (2017) 130 (Supplement 1): 2013.

https://doi.org/10.1182/blood.V130.Suppl_1.2013.2013

Published: 2017

Journal Articles

A Multicenter, Retrospective Data Collection Study on the Compassionate Use of a Plasma-Derived Factor X Concentrate to Treat Patients with Hereditary Factor X Deficiency

James N. Huang, MD, Ri Liesner, Chioma Akenezi, BSc, PgDip, Steven K. Austin, BMedSci, MBBS, Kaan Kavakli, MD

Blood (2017) 130 (Supplement 1): 3736.

https://doi.org/10.1182/blood.V130.Suppl_1.3736.3736

Published: 2017

Journal Articles

Comparison of Different Phenotypes of Bernard-Soulier Syndrome

Maria A. Kumskova, MD, Nadezhda Zozulya, MD PhD, Valentina N. Dvyrnik, MD PhD, Elena Likhachyova, MD PhD, Elena Yakovleva, MD PhD, Valeriy G. Savchenko

Blood (2017) 130 (Supplement 1): 4856.

https://doi.org/10.1182/blood.V130.Suppl_1.4856.4856

Published: 2017

NARROW

Results of PAC203: A Randomized Phase 2 Dose-Finding Study and Determination of the Recommended Dose of Pacritinib

Post-Transplant Cyclophosphamide in Allogeneic Bone Marrow Transplantation for the Treatment of Benign Hematologic Diseases

In-Hospital Mortality and Morbidity Among Patients Presenting with Intracranial Hemorrhage: A Single Center's Experience with Vitamin K Antagonists and the Direct Oral Anticoagulants

Efficacy and Safety of CPX-351 Versus 7+3 in a Phase 3 Exploratory Analysis in Patients with High-Risk/Secondary Acute Myeloid Leukemia (AML) with Prior Hypomethylating Agent Exposure Who Achieved Remission

An Analysis from the WM UK Rory Morrison Registry - How Does Waldenström's Macroglobulinemia Affect Younger Patients?

Risk of Hemorrhage in Patients with Polycythemia Vera Exposed to Aspirin in Combination with Anticoagulants: Results of a Prospective, Multicenter, Observational Cohort Study (REVEAL)

Blinatumomab in Combination with Pembrolizumab Is Safe for Adults with Relapsed or Refractory B-Lineage Acute Lymphoblastic Leukemia: University of California Hematologic Malignancies Consortium Study 1504

Venetoclax and Cytarabine in AML Transformed from Myelofibrosis

A Prospective, Open-Label, Multicenter, Phase 2 Trial to Evaluate the Safety and Efficacy of the Combination of Tirabrutinib (ONO/GS-4059) and Entospletinib with and without Obinutuzumab in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL)

A Phase 1 First-in-Human Study of AMG 330, an Anti-CD33 Bispecific T-Cell Engager (BiTE ® ) Antibody Construct, in Relapsed/Refractory Acute Myeloid Leukemia (R/R AML)

Characteristics of Patients (pts) Who Relapse and Die of Multiple Myeloma (MM) within One Year Post Frontline Autologous Stem Cell Transplant (ASCT) in the Novel Agent Era: An Ultra-High Risk Population

Low-Dose Lenalidomide Maintenance after Induction Therapy in Older Patients with Primary CNS Lymphoma

Safety and Efficacy of Acalabrutinib Plus Bendamustine and Rituximab (BR) in Patients with Treatment-Naive (TN) or Relapsed/Refractory (R/R) Mantle Cell Lymphoma (MCL)

Low Molecular Weight Heparin (LMWH) for Venous Thromboembolism (VTE) Prophylaxis in Patients with Primary Central Nervous System Lymphoma (PCNSL)

Comparison of Efficacy and Toxicity of CD19-Specific Chimeric Antigen Receptor T-Cells Alone or in Combination with Ibrutinib for Relapsed and/or Refractory CLL

Up to 7 Years of Follow-up of Single-Agent Ibrutinib in the Phase 1b/2 PCYC-1102 Trial of First Line and Relapsed/Refractory Patients with Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

Intracranial Hemorrhage in Children with Inherited Bleeding Disorders: A Single Center Study in China

Outcomes of Autologous Stem Cell Transplantation in Very Elderly Patients with Multiple Myeloma

A Multicenter, Retrospective Data Collection Study on the Compassionate Use of a Plasma-Derived Factor X Concentrate to Treat Patients with Hereditary Factor X Deficiency

Comparison of Different Phenotypes of Bernard-Soulier Syndrome

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only